Jul 1
Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP
This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be ... Show More
29m 16s
Jun 24
Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory
This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on t ... Show More
25m 45s
Jun 17
Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management
This week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do once we make the diagnosis? How do we approach management when we have a new diagnosis? Content: - Refres ... Show More
26m 41s
Nov 2021
Machine learning in classification of AML, aging bone marrow in leukemia, and treating bleeding disorders of unknown cause
In this week’s episode, we’ll learn more about the application of machine learning in molecular subclassification and prognostication of acute myeloid leukemia or AML, discuss the role of aging bone marrow in leukemia progression, and learn more about the challenges in treating b ... Show More
19m 25s
Oct 2024
254. Months of Monocytosis – An approach to CMML
Send us Fan MailIn this episode, we discuss the clinical presentation, work-up, and treatment of CMML. Our medicine minute discusses emerging evidence on the use of ruxolitinib for CMML treatment. Written by: Dr. Elliot Smith (Internal Medicine Resident)Reviewed by: Dr. Stephanie ... Show More
17m 17s
May 2025
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesios ... Show More
19m 58s
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
This week, we move to our next phases of therapy for AML, which are consolidation and maintenance. Be sure to check out our prior episodes for a discussion on initial workup and how we incorporate recurrent genetic abnormalities into how we think about AML. Check out figure 1 from this paper for a helpful diagram!
Episode contents:
- A recap on approach to ... Show More
